Coherus Oncology announces common stock offering, no amount given

Coherus Oncology (CHRS) announced a proposed underwritten public offering of its common stock. All of the shares in the offering are being offered by Coherus. Coherus intends to use the net proceeds from the proposed offering to support the ongoing commercialization of LOQTORZI, to continue clinical development of its product candidates, and for working capital and other general corporate purposes. TD Cowen, Guggenheim Securities, and Oppenheimer & Co. are acting as joint bookrunners for the proposed offering.